Workflow
多维双层片
icon
Search documents
新品大年重塑增长 汤臣倍健称要做出更多心动和自豪的产品
2025三季度财报发布,膳食营养补充剂(VDS)龙头企业汤臣倍健交出复苏答卷:营收、净利润同比双增,第三 季度营收同比增长23.45%,且前三季度利润同比恢复增长,经营能力逐季改善。 汤臣倍健董事长梁允超在30周年庆典上说道:"不在'品牌和产品创新'的餐桌上,就在'渠道'的菜单上。"业绩修复 的背后,是一场以用户价值为核心、贯穿研发、品牌、渠道全链路的价值链深度变革,更是汤臣倍健从行业变局 中探索新增长路径的必然结果。 行业重构期,锚定用户价值打破迷局 面对消费变局,不同行业都在求突围,但唯有企业经营数据才是见真章的"试金石"。 汤臣倍健的改革,不是为了应对业绩下跌的临时之举,而是长期主义战略的延续和深化。 VDS行业增速放缓,线下药店作为传统基本盘,一边受医保政策影响,一边面临客流下滑,品牌和渠道不再紧密 合作,反而变成利益博弈;线上渠道则陷入低价、同质化混战,企业盈利空间被挤压。 与此同时,消费需求在升级。普通消费者看重"同价位里品质最好"的质价比,高端用户则愿意为"实打实的科学功 能"和专业价值买单。过去那种"一刀切"的产品供给,跟不上市场需求的分化节奏。 危中有机,行业结构性机会依然清晰。2024年中 ...
新品大年重塑增长,汤臣倍健称要做出更多心动和自豪的产品
Core Insights - The core viewpoint of the article emphasizes that the operational data of companies serves as a true measure of their performance amidst changing consumer dynamics, with Tongrentang's (汤臣倍健) recent financial results showcasing a recovery in revenue and net profit [1][12] Group 1: Company Performance - Tongrentang reported a 23.45% year-on-year increase in revenue for Q3 2025, with profits also showing recovery in the first three quarters [1][12] - The company launched 71 new products in the first three quarters of 2025 and holds 487 domestic and international patents, indicating a strong focus on innovation [4][12] Group 2: Strategic Transformation - The company's reform is a continuation of its long-term strategy rather than a temporary response to declining performance, focusing on user value and breaking away from past dependencies [3][12] - Tongrentang's "strong technology transformation" strategy aims to enhance product strength and technological competitiveness, with a commitment to user needs as the core of its growth path [3][4] Group 3: Market Dynamics - The VDS industry is experiencing a slowdown, with traditional offline pharmacies facing challenges from policy changes and reduced foot traffic, while online channels are struggling with price wars and homogenization [3][6] - Despite these challenges, the VDS market is projected to grow by 3.7% in 2024, outpacing the 1.7% growth of the fast-moving consumer goods market [3] Group 4: Product and Channel Strategy - Tongrentang is building a dual-engine product matrix of "basic mass products + segmented functional products" to address both general market needs and specialized high-value areas [9][10] - The company is shifting its channel strategy from a focus on quantity to a model of empowerment and profit-sharing, enhancing collaboration with pharmacies and leveraging digital tools for efficient operations [10][11] Group 5: Brand Positioning - Tongrentang is enhancing its brand image through partnerships in scientific exploration and health initiatives, reinforcing its trust and credibility in the market [11][12] - The company aims to create a complete value chain centered on user health, integrating R&D, branding, and channels to meet real consumer needs [12][13]
三季度营收净利同比增长,汤臣倍健靠什么突围?
Nan Fang Du Shi Bao· 2025-10-31 09:32
Core Viewpoint - The leading dietary supplement company, Tongrentang, reported significant growth in Q3 2023, with revenue reaching 1.383 billion yuan, a year-on-year increase of 23.45%, and net profit attributable to shareholders at 170 million yuan, up 861.91% [1] Financial Performance - In Q3 2023, Tongrentang achieved a revenue of 1.383 billion yuan, marking a 23.45% increase year-on-year - The net profit attributable to shareholders was 170 million yuan, reflecting an 861.91% increase year-on-year - The non-recurring net profit was approximately 133 million yuan, showing a 652.64% year-on-year growth - For the first nine months of 2023, the net profit attributable to shareholders increased by 4.45% compared to the same period last year, while the non-recurring net profit rose by 2.44% [1] Product Innovation - Tongrentang launched 71 new products in the first three quarters of 2023, with new product sales accounting for over 20% for the first time - The company is focusing on user needs, with 68% of consumers under 35 preferring products based on "scenario-based functions" rather than brand alone [3] - The new "multi-layer tablet" product achieved sales of over 10 million yuan within 45 days of launch, showcasing effective market positioning [3] - The company is adapting to industry innovation trends, shifting from merely adding new ingredients to ensuring scientific validation and scenario relevance [4] Channel Reconstruction - Tongrentang is addressing the common industry issue of online and offline channel conflicts by implementing separate inventory strategies for each channel - The offline strategy targets the mass market with high cost-performance products, while the online strategy focuses on professional, niche, and high-end products [7] - The company is enhancing channel service by training pharmacy staff to become "health consultants," improving both user experience and store revenue [8] Industry Insights - The dietary supplement (VDS) industry is experiencing a "Matthew Effect," where leading brands are gaining market share through R&D and channel strategies, while smaller brands struggle with price competition [9] - The market share of the top five brands in the VDS industry is projected to increase to 38% by 2025, up 6 percentage points from 2023 [10] - Tongrentang's international business has become a new growth point, with overseas revenue reaching 720 million yuan, a year-on-year increase of 13.64% [10] Future Outlook - The company plans to adopt a "re-entrepreneurial" mindset over the next five years, focusing on long-term brand investment despite short-term profit sacrifices [11] - Tongrentang emphasizes the importance of responding quickly to user needs and maintaining operational quality to sustain growth in a challenging market [13]
汤臣倍健第三季度营收同比增长23.45% 新品迭代与品类扩张提速
Zheng Quan Ri Bao Wang· 2025-10-29 11:46
Core Insights - Tongrentang's Q3 2025 report shows a revenue of 1.383 billion yuan, a year-on-year increase of 23.45%, with a net profit of 170 million yuan for the quarter and a total revenue of 4.915 billion yuan and net profit of 907 million yuan for the first three quarters [1][2] Group 1: Product Innovation and Strategy - Since 2025, the company has focused on product innovation, launching 71 new products in the first three quarters, with a dual strategy of upgrading basic nutrients and breaking into professional functional categories [1][2] - The company has extended its product line into high-barrier functional categories, launching its first OTC glucosamine product offline and a special medical purpose formula food online in September [1] Group 2: Channel Strategy and Market Performance - Tongrentang has implemented a differentiated product strategy for online and offline channels, optimizing the channel value chain, with improvements in operational quality [2] - The company has seen significant performance in e-commerce, with new products like multi-layer tablets and adult calcium series driving market share growth [2] Group 3: R&D and Compliance - Under the "Scientific Nutrition" strategy, the company has advanced R&D in new materials, functions, and technologies, holding 487 patents and numerous health food certifications, indicating strong technical reserves and compliance capabilities [2] - Systematic adjustments across products, channels, R&D, and branding since 2024 have shown quick reform results, demonstrating the company's operational resilience [2]
汤臣倍健:2025年第三季度营收同比增长23.45%,加速新品迭代与品类扩张
Core Insights - The company reported a significant increase in revenue and net profit for Q3 2025, with revenue reaching 1.383 billion yuan, a year-on-year growth of 23.45%, and net profit of 170 million yuan, marking a remarkable year-on-year increase of 861.91% [2] Financial Performance - For the first three quarters of 2025, the company achieved a total revenue of 4.915 billion yuan and a net profit of 907 million yuan, indicating a recovery in profitability and operational capability [2] - The company has shown consistent improvement in its financial metrics, with both revenue and profit increasing year-on-year [2] Product Innovation and Strategy - The company has focused on product innovation as a key strategy, launching 71 new products in the first three quarters of 2025 [2] - The product strategy includes a dual approach of upgrading basic nutrients and breaking into specialized functional categories, which strengthens its presence in the mass consumer market while also targeting professional sectors [2][3] Market Demand and Consumer Engagement - The company has effectively driven category growth in the basic nutrient sector by promoting high cost-performance products, which has broadened its customer base [3] - New products such as the adult calcium series with high vitamin K2 content have led to a 48% growth in the liquid calcium category on e-commerce platforms [3] Channel Strategy - The company has implemented a differentiated inventory strategy to optimize the value chain across online and offline channels, with positive results beginning to show [4] - In offline channels, the company has improved its market share in the protein powder category by 3.3 percentage points year-on-year, driven by products like calcium vitamin E protein powder [4] Research and Development - The company has made significant advancements in R&D, holding 487 patents and numerous certifications for health food products, positioning itself at the forefront of the industry [5] - The company has also established partnerships for scientific exploration, enhancing its brand image and credibility in the market [5] Future Outlook - Following a period of adjustment, the company is expected to stabilize and recover, laying a solid foundation for long-term growth as new products continue to be released and operational efficiency improves [6]
汤臣倍健2025第三季度营收同比增长23.45% 加速新品迭代与品类扩张
Zhong Guo Jing Ji Wang· 2025-10-29 09:13
Core Insights - The company reported a significant increase in both revenue and net profit for the third quarter of 2025, with revenue reaching 1.383 billion yuan and net profit at 170 million yuan, marking a year-on-year profit growth of 861.91% [1] - For the first three quarters of 2025, total revenue was 4.915 billion yuan, with a net profit of 907 million yuan, indicating a recovery in profitability and operational capability [1][5] Product Innovation - The company has focused on product innovation as a key strategy, launching a total of 71 new products in the first three quarters of 2025 [3] - The product strategy includes a dual approach of upgrading basic nutrients and breaking into specialized functional categories, which strengthens the consumer market while expanding into professional fields [3] - Notable product launches include a high-content vitamin K2 adult calcium series, which drove a 48% growth in the liquid calcium category, and a multi-layer tablet that continues to boost category growth [3] Channel Strategy - The company has implemented a differentiated inventory strategy to optimize the value chain across online and offline channels, with positive adjustments becoming evident [4] - In offline channels, the company has improved market share in the protein powder category by 3.3 percentage points, driven by the calcium vitamin E protein powder [4] - Online, the company has focused on professional, segmented, and high-end upgrades, with new products performing well on e-commerce platforms, including a new high-content vitamin K2 liquid calcium series targeting specific demographics [4] Research and Development - The company has made significant advancements in research and development, holding 487 patents and numerous certifications for health food products, positioning itself at the forefront of the industry [5] - The company has also enhanced its brand image by becoming a partner in significant scientific exploration projects, further establishing its professional reputation [5] Overall Performance - Following a challenging year in 2024, the company has shown resilience through systematic adjustments across various dimensions, achieving notable reform results in a short time [5] - The ongoing release of new products and improvements in operational efficiency are expected to stabilize and support long-term growth [5]
汤臣倍健董事长梁允超:三十而砺再创业
Sou Hu Cai Jing· 2025-10-28 13:20
Core Viewpoint - The company is facing significant challenges and aims to adopt a "re-entrepreneurial" mindset to achieve new revenue highs from 2026 to 2028, outperforming industry growth rates across all channels [2][5][11]. Group 1: Company Strategy and Goals - The company plans to complete a digital infrastructure for pharmacies and explore new business models to create greater value for consumers and partners [10]. - From 2026 to 2028, the company aims to achieve revenue growth that surpasses the growth rates of the VDS category, focusing on various channels including traditional e-commerce and international markets [11][18]. - The company emphasizes the importance of product innovation, with a focus on new functional products and dosage forms, aiming for a significant portion of new product sales to exceed 20% in 2025 [12]. Group 2: Market Challenges and Opportunities - The company acknowledges missing the opportunity to capitalize on the new cycle of dietary supplements in 2023, which has led to significant setbacks [4][5]. - External factors such as healthcare policies and declining purchasing power have negatively impacted the VDS category, while internal factors include the lack of growth in key channels [5][6]. - The company recognizes that the current challenges present opportunities for growth and innovation, stating that crises can lead to new opportunities [8][9]. Group 3: Brand and Innovation Focus - The company is committed to investing in brand development and product innovation, even at the cost of short-term profits, as brand strength is seen as a core competitive advantage [14][15]. - The company aims to leverage AI technology to enhance product offerings and ensure that scientific nutrition remains a focal point in the market [13][20]. - The company is also focused on expanding its global market presence and fostering new growth engines through innovative projects [15].
汤臣倍健:2025年上半年营收35.32亿元 二季度净利润同比增速回正
Zhong Zheng Wang· 2025-08-11 02:26
Core Viewpoint - Tongrentang's revenue and net profit showed signs of recovery in the first half of 2025, driven by innovative products and operational improvements [1][2] Group 1: Financial Performance - In the first half of 2025, Tongrentang achieved a revenue of 3.532 billion yuan and a net profit of 737 million yuan [1] - The revenue decline in Q2 narrowed year-on-year, and net profit growth turned positive [1] Group 2: Market Trends and Product Strategy - The sales growth of dietary supplements in pharmacies declined by approximately 25% from January to May 2025 [1] - Tongrentang focuses on consumer-centric strategies, emphasizing basic nutrients with high penetration and frequency of purchase, while also enhancing high-quality functional products [1] - New products have shown growth, contributing to an increase in market share [1] Group 3: Product Performance - In May 2025, Tongrentang's protein powder, calcium DK, glucosamine, and Lifespace probiotics saw a sequential increase in market share due to new product launches [1] - Online, key products like the premium protein powder and liquid calcium ranked in the top 10 new products on Tmall during the "618" shopping festival [1] Group 4: Research and Development - Tongrentang is advancing its research in anti-aging, precision nutrition, and biosynthesis technologies [2] - Recent research findings on natural anti-aging components were published in the journal "Aging Cell," and Tongrentang was featured in "Nature" for its scientific achievements [2] Group 5: Future Outlook - According to Guosheng Securities, starting from Q2 2025, Tongrentang's performance is expected to improve gradually due to demand recovery, new product launches, and operational efficiency [2] - The company is also accelerating its expansion into overseas markets, which may contribute to performance stabilization and growth [2]
汤臣倍健上半年营收35.32亿元高质量新品破局战术初见成效
Xin Lang Cai Jing· 2025-08-08 21:13
Core Viewpoint - The company reported a revenue of 3.532 billion yuan and a net profit of 737 million yuan for the first half of 2025, driven by innovative products and operational improvements [1] Group 1: Financial Performance - The company achieved a revenue of 3.532 billion yuan and a net profit of 737 million yuan during the reporting period [1] - The performance reflects the impact of innovative product offerings and enhanced operational efficiency [1] Group 2: Product Strategy - The company focused on basic nutrient categories that are widely consumed and frequently purchased, aiming to provide high cost-performance products [1] - New products such as protein powder, calcium DK, glucosamine, and probiotics have contributed to a rebound in market share [1] - The calcium DK product, in particular, showed significant customer acquisition effects during initial trials [1] Group 3: Market Positioning - The company's main brand products, including premium protein powder and liquid calcium, performed well, ranking in the top 10 of new products on Tmall during the "618" shopping festival [1] - Data from JD platform indicates a breakthrough in product features, enhancing competitive positioning [1] Group 4: Research and Development - The company is advancing the application of research outcomes in product development, focusing on areas such as anti-aging and precision nutrition [1] - A study on natural anti-aging conducted in collaboration with institutions was published in the international journal "Aging Cell" [1] Group 5: International Expansion - The company is accelerating its overseas market expansion and actively exploring new growth opportunities abroad [1]
汤臣倍健今年上半年营收35.32亿,新品连发带动品类曲线回调
Zhong Guo Jing Ji Wang· 2025-08-08 13:37
Core Insights - The company reported a revenue of 3.532 billion yuan and a net profit of 737 million yuan for the first half of 2025, showing a narrowing decline in revenue and a positive growth rate in net profit in the second quarter [1] Group 1: Financial Performance - The revenue for the first half of 2025 was 3.532 billion yuan, with a net profit of 737 million yuan attributed to the company's innovative product drive and operational efficiency improvements [1] - The second quarter saw a year-on-year reduction in revenue decline, while net profit growth turned positive [1] Group 2: Market Trends and Strategies - Sales of dietary supplements in pharmacies saw a year-on-year decline of approximately 25% from January to May 2025, prompting the company to focus on consumer-centered solutions [3] - The company is concentrating on basic nutrient categories with high penetration and frequency of purchase, while also enhancing high-quality, cost-effective products [3] - New product launches have shown growth, contributing to an increase in market share, with notable performance in both offline and online channels [3] Group 3: Research and Development - The company is advancing its research in areas such as anti-aging, precision nutrition, and biosynthesis technology, with recent findings published in prestigious journals [4] - The company has partnered with China's Antarctic research team to provide specialized nutritional products, showcasing its commitment to leveraging research for product innovation [4] Group 4: Future Outlook - According to industry reports, the company is expected to see improved performance starting from the second quarter of 2025 due to easing base pressure, demand recovery, new product launches, and operational efficiency [4] - The company is also accelerating its expansion into overseas markets, aiming to create more health value for consumers as new products continue to be released [4]